^
    Back
    Association details:
    Biomarker:EGFR mutation
    Cancer:Non Small Cell Lung Cancer
    Drug:irinotecan (Topoisomerase I inhibitor) +
    Teysuno (gimeracil/oteracil/tegafur) (Thymidylate synthase inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: C3 – Early Trials
    Source:
    Med Oncol
    Title:

    Phase II study of S-1 and irinotecan combination therapy in EGFR-mutated non-small cell lung cancer resistant to epidermal growth factor receptor tyrosine kinase inhibitor: North Japan Lung Cancer Study Group Trial 0804 (NJLCG0804)

    Published date:
    08/16/2022
    Excerpt:
    We conducted a multicenter phase II trial to evaluate the efficacy and safety of S-1 and irinotecan combination therapy in patients with epidermal growth factor receptor-mutated non-small-cell lung cancer treated with epidermal growth factor receptor tyrosine kinase inhibitors....Progression-free survival and overall survival were 5.0 and 17.1 months, respectively. The overall response rate was 52.0%.
    DOI:
    https://doi.org/10.1007/s12032-022-01755-3